$513 Million is the total value of TCG Crossover Management, LLC's 22 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 23.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | IVERIC BIO INC | $125,083,401 | +13.6% | 5,141,118 | 0.0% | 24.38% | +25.5% | |
| COGT | COGENT BIOSCIENCES INC | $39,178,943 | -6.7% | 3,631,042 | 0.0% | 7.64% | +3.1% | |
| GERN | Buy | GERON CORP | $38,550,512 | +4.9% | 17,765,213 | +17.0% | 7.51% | +15.8% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $36,318,892 | -56.6% | 149,917 | -48.0% | 7.08% | -52.0% |
| TYRA BIOSCIENCES INC | $31,964,885 | +111.4% | 1,989,103 | 0.0% | 6.23% | +133.5% | ||
| Buy | VENTYX BIOSCIENCES, INC | $27,326,754 | +5.9% | 815,724 | +3.6% | 5.33% | +16.9% | |
| KALV | KALVISTA PHARMACEUTICALS, INC | $26,688,591 | +16.3% | 3,395,495 | 0.0% | 5.20% | +28.4% | |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $26,580,801 | -28.2% | 3,048,257 | -48.4% | 5.18% | -20.7% |
| VECT | Buy | VECTIVBIO HOLDING AG | $26,496,736 | +31.1% | 3,113,600 | +33.4% | 5.16% | +44.8% |
| AVTE | AEROVATE THERAPEUTICS INC | $21,809,297 | -31.2% | 1,081,274 | 0.0% | 4.25% | -24.0% | |
| DYN | New | DYNE THERAPEUTICS, INC | $19,009,728 | – | 1,650,150 | +100.0% | 3.70% | – |
| KURA | KURA ONCOLOGY INC | $17,411,142 | -1.5% | 1,423,642 | 0.0% | 3.39% | +8.9% | |
| VRDN | Sell | VIRIDIAN THERAPEUTICS, INC | $16,882,238 | -41.2% | 663,610 | -32.5% | 3.29% | -35.1% |
| SLN | SILENCE THERAPEUTICS PLCads | $13,050,225 | -59.3% | 2,104,875 | 0.0% | 2.54% | -55.1% | |
| IMVT | Sell | IMMUNOVANT, INC | $10,156,770 | -33.1% | 654,853 | -23.4% | 1.98% | -26.1% |
| ENTRADA THERAPEUTICS INC | $8,481,848 | +7.2% | 584,955 | 0.0% | 1.65% | +18.4% | ||
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $8,326,500 | – | 350,000 | +100.0% | 1.62% | – | |
| MRUS | MERUS BV | $5,520,000 | +18.9% | 300,000 | 0.0% | 1.08% | +31.4% | |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $4,286,398 | -76.2% | 529,839 | -53.7% | 0.84% | -73.7% |
| CABA | CABALETTA BIO, INC | $4,025,795 | -10.6% | 486,795 | 0.0% | 0.78% | -1.3% | |
| CCCC | New | C4 THERAPEUTICS, INC. | $3,925,000 | – | 1,250,000 | +100.0% | 0.76% | – |
| ALPN | ALPINE IMMUNE SCIENCES INC | $1,953,693 | +5.0% | 253,069 | 0.0% | 0.38% | +16.2% | |
| ELEV | Exit | ELEVATION ONCOLOGY INC | $0 | – | -288,390 | -100.0% | -0.05% | – |
| Exit | MOONLAKE IMMUNOTHERAPEUTICS | $0 | – | -1,000,000 | -100.0% | -1.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.